Results 31 to 40 of about 1,993 (117)

π‐Extended COUPY Fluorophores for Targeted Near‐Infrared Fluorescence and Lifetime Imaging in Live Cells

Angewandte Chemie, Volume 138, Issue 34, 17 August 2026.
π‐Extended COUPY dyes, obtained by vinylogation of coumarin‐based COUPY scaffolds, shift absorption, and emission deep into the NIR region while preserving compactness and synthetic accessibility. These bright, photostable dyes enable live‐cell imaging, FLIM, and site‐specific peptide conjugation, offering a modular platform for targeted bioimaging and
Diego Abad‐Montero, Manel Bosch, Rodrigo Garcés‐Castellanos, Michael Q. Schottenhamel, Sergio Pedraza‐Arevalo, Alejandro Ibáñez‐Costa, Justo P. Castaño, Tania García‐Becerra, Elena Rebollo, Marta E. Alberto, Antonio Francés‐Monerris, Vicente Marchán   +11 more
wiley   +2 more sources

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy

Frontiers in Endocrinology
BackgroundPeptide receptor radionuclide therapy (PRRT) is a well-established treatment option for neuroendocrine tumors (NET), yet randomized controlled trials have not provided data on its impact on overall survival.
Annie Mathew, David Kersting, Wolfgang P. Fendler, Johanna Braegelmann, Dagmar Fuhrer, Harald Lahner   +5 more
doaj   +1 more source

The evolving role of targeted radioligand therapy in small cell and non-small cell lung cancer: a systematic review [PDF]

Exploration of Targeted Anti-tumor Therapy
Background: Targeted radioligand therapy (TRT) is an emerging theranostic modality in oncology. While well established in neuroendocrine and prostate cancers, its role in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) remains ...
Serin Moghrabi, Saad Ruzzeh, Kamal Al-Rabi, Ahmed Abdlkadir, Mohammed J. Al-Jaghbeer, Nouraldeen Alzorgan, Ula Al Rasheed, Mohammad Alqudah, Akram Al-Ibraheem   +8 more
doaj   +1 more source

Table_1_New Insights in PRRT: Lessons From 2021.docx

, 2022
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further ...
Giulia Puliani (10692075), Marilda Mormando (12344704), Rosa Lauretta (12344707), Marialuisa Appetecchia (7539743), Marta Bianchini (715381), Alfonsina Chiefari (12344701)   +5 more
core   +1 more source

PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) [PDF]

Peptide receptor radionuclide therapy (PRRT) has been primarily studied in low and intermediate-grade digestive neuroendocrine tumors (NET G1-G2). The documentation of a similar benefit for high-grade digestive neuroendocrine neoplasms (NEN) has been ...
Kong, Grace, Grozinsky-Glasberg, Simona, Strosberg, Jonathan, Sorbye, Halfdan   +3 more
core   +2 more sources

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres

Current Oncology
Pancreatic neuroendocrine tumors (pNETs) are rare but increasingly prevalent malignancies with varied prognoses and a diverse range of treatment options, including surgery, somatostatin analogues (SSAs), chemotherapy, targeted therapy, and peptide ...
Gautham Nair, Morgan Black, Kathie Baer, Stephen Welch, David T. Laidley, Rachel Goodwin, Macyn Leung, William J. Phillips, Michael Vickers, Tim Asmis, Horia Marginean, Elena Tsvetkova   +11 more
doaj   +1 more source

Perioperative Outcomes of Patients With Pancreatic Neuroendocrine Neoplasms in the Context of Different Body Composition Phenotypes

World Journal of Surgery, EarlyView.
Pancreatic neuroendocrine neoplasms (pNEN) are rare and heterogeneous tumors with increasing incidence. While surgical resection remains the only curative treatment, perioperative outcomes are influenced by patient‐related risk factors. Recent research highlights body composition (BC) as a prognostic marker in oncological and transplantation surgery ...
Fabiola A. Bechtiger, Mariah Herbrich, Hazem K. A. A. Hassan, Jörg Kaiser, Thomas Hank, Magdalena Lewosinska, Deniz Uluk, Osman Öcal, Nicole D. Hildebrand, Steven WM Olde Damink, Franck Billmann, Zoltan Czigany, Mohammed Al‐Saeedi   +12 more
wiley   +1 more source

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)

Microbiology Spectrum, 2022
As dolutegravir (DTG)-containing HIV regimens are scaled up globally, monitoring for HIV drug resistance (HIVDR) will become increasingly important.
Joshua DeVos, Kimberly McCarthy, Victor Sewe, Grace Akinyi, Muthoni Junghae, Valarie Opollo, Janin Nouhin, Robert Shafer, Clement Zeh, Artur Ramos, Heather Alexander, Joy Chang   +11 more
doaj   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor

Endocrine Oncology
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary,
Katherine I Wolf, Zhonglin Lu, Elizabeth A Hesseltine, Ka-Kit Wong, Francis P Worden, Tobias Else   +5 more
doaj   +1 more source